Merger remains the main story as cash falls and legacy trials wind down

The quarter itself offers no clear beat or miss. No published consensus is provided in the filing, and the merger with Avere was already announced on July 14, 2026; therefore, this report mainly confirms the expected transition rather than introducing a fresh surprise. The financial picture is best read against NextCure’s own prior period, not against a reliable external forecast.

Cost reductions are real but mostly defensive. R&D expense dropped by $16.7 million year over year because the prior-year quarter included $17.0 million of license fees, while G&A fell only $0.6 million. The $5.1 million impairment charge reflects facility and asset downsizing, so the lower net loss is primarily a result of reduced activity and one-time comparison effects rather than improving operating momentum (Financial Results; Selected Statement of Operations Items).

Liquidity is tightening ahead of the transaction. Cash, cash equivalents and marketable securities declined to $20.1 million from $41.8 million at December 31, 2025, with $23.1 million used in operations during the first half or quarter-specific period described in the release. Management is explicitly preserving capital to support the merger closing, which signals that the standalone NextCure business is being managed for transition rather than continued independent investment (Financial Results; Selected Balance Sheet Items).

The legacy pipeline has been materially de-risked by stopping investment, not by producing clinical validation. U.S. enrollment activity for SIM0505 has been halted, with the company now seeking to preserve or monetize the asset. LNCB74 is more constructive operationally because LigaChem elected to continue development as sole developing party, but NextCure’s economics are limited to potential future milestones and royalties rather than ongoing control of development (About SIM0505; About LNCB74).

Net read: strategically consequential but financially mixed. The proposed Avere merger and expected $320 million financing provide the prospective capital base, while CVRs preserve a possible claim on specified NextCure assets. However, the financing is subject to closing conditions, the merger still requires stockholder approval, and the quarter shows a shrinking cash balance, impairment charges, and suspended activity in the lead legacy program. Relative to what was already known after the July 14 announcement, this filing mostly confirms a wind-down-and-transition scenario rather than improving the standalone outlook (About the Merger; Recent Business Highlights).